Skeletal complications of ADT: disease burden and treatment options. - Wikidata - awgldk - TriplyDB

Skeletal complications of ADT: disease burden and treatment options.

Skeletal complications of ADT: disease burden and treatment options.

http://www.wikidata.org/entity/Q37074106

about

Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction.Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer

P2860

Q37650625-C1BB2280-A7D9-485F-8E3D-73257C9361BC Q58294554-8CB9D40D-518F-48EF-9493-08B3AE975E61

P2860

Skeletal complications of ADT: disease burden and treatment options.

http://www.wikidata.org/entity/Q37074106

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Skeletal complications of ADT: disease burden and treatment options.

@en

Skeletal complications of ADT: disease burden and treatment options.

@nl

type

label

Skeletal complications of ADT: disease burden and treatment options.

@en

Skeletal complications of ADT: disease burden and treatment options.

@nl

prefLabel

Skeletal complications of ADT: disease burden and treatment options.

@en

Skeletal complications of ADT: disease burden and treatment options.

@nl

P1433

Q37074106-2FD58770-63F0-4F4D-B67A-CC6B09F7966B

P1476

Q37074106-BD2E39D2-E19F-4139-8672-1A1B5DDDC8A7

P2093

Q37074106-328C44C0-91FB-486C-8B54-7046020269F4

P2860

Q37074106-10884C5E-16E9-49D8-9096-E6122377A413

Q37074106-11229AFF-72CF-4950-BC8F-98482505E4EE

Q37074106-2050CD06-B222-490D-BABD-2854890EFE9B

Q37074106-29870489-012C-4891-85CB-866178E5AFAB

Q37074106-40D21FF0-785D-41D4-9572-D5D27F49E403

Q37074106-63F61FEC-B822-46DB-B56E-32AA6F99A8CF

Q37074106-65649C15-F996-46BF-9C02-AF72729A6F4B

Q37074106-69813CD3-0B57-409D-B872-02839F60026F

Q37074106-6E974091-A21F-432A-AF08-FE592155020D

Q37074106-77016537-C7F5-44AF-B5C3-DC251B0EA818

P304

Q37074106-85ACA56F-0E12-46C9-BD60-C019D47A583E

P31

Q37074106-67603FB1-5A0B-4B94-A137-54D22D4B43B7

P356

Q37074106-DEF1E502-72DF-43F3-B3B0-51DA7BADADFA

P433

Q37074106-01961B87-E185-45BD-B629-CBDB3687AFE3

P478

Q37074106-ACD48279-EAD9-4689-922F-948A43F611B4

P50

Q37074106-AF1B838D-DDD5-4AA6-BB11-BC3E265FD332

P577

Q37074106-7B13BDD4-1223-45AF-A140-C5050BF1DA81

P5875

Q37074106-D50032DA-CB5E-4559-8FFC-CCF56305829C

P698

Q37074106-472A1ABD-C438-4DB0-B465-CABB8D031598

P932

Q37074106-E8E05CF8-E537-4C59-A215-6EE0FDE11221

P356

P1433

Asian Journal of Andrology

P1476

Skeletal complications of ADT: disease burden and treatment options

@en

P2093

Jacques Planas Morin

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer

Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Crosstalk between cancer cells and bone microenvironment in bone metastasis.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

P304

670-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2012.70

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Juan Morote Robles

P577

2012-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230697838

http://www.w3.org/2001/XMLSchema#string

P698

22902912

http://www.w3.org/2001/XMLSchema#string

P932

3734975

http://www.w3.org/2001/XMLSchema#string